Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575823 | 0.89 | PPARG (0.45) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL4575252 | 0.82 | PPARG (0.52) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL4575771 | 0.80 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL4575733 | 0.78 | PPARA (0.46) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL4575576 | 0.78 | PPARA (0.50) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| SCHEMBL4576167 | 0.76 | PPARA (0.42) | PPARGPPARAPPARD | |
| SCHEMBL4576122 | 0.76 | PPARA (0.56) | PPARGPPARAPPARD | |
| SCHEMBL11063546 | 0.75 | PPARA (0.56) | PPARGPPARATBXAS1 | |
| SCHEMBL4575129 | 0.75 | PPARA (0.44) | PPARGPPARAPPARD | |
| SCHEMBL4575605 | 0.75 | PPARA (0.48) | PPARGPPARAPPARDADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.